Top

20-01-2017 | Nausea and vomiting | Article

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK₁) receptor antagonists

Journal: Supportive Care in Cancer

Authors: Snežana M. Bošnjak, Richard J. Gralla, Lee Schwartzberg

Publisher: Springer Berlin Heidelberg

Abstract

Chemotherapy-induced nausea (CIN) has a significant negative impact on the quality of life of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT₃) receptor antagonists (RAs) has reduced the risk of vomiting, but (except for palonosetron) their effect on nausea, especially delayed nausea, is limited. This article reviews the role of NK₁RAs when combined with 5-HT₃RA–dexamethasone in CIN prophylaxis. Aprepitant has not shown consistent superiority over a two-drug (ondansetron–dexamethasone) combination in nausea control after cisplatin– or anthracycline–cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC). Recently, dexamethasone and dexamethasone–metoclopramide were demonstrated to be non-inferior to aprepitant and aprepitant–dexamethasone, respectively, for the control of delayed nausea after HEC (AC/cisplatin), and are now recognized in the guidelines. The potential impact of the new NK₁RAs rolapitant and netupitant (oral fixed combination with palonosetron, as NEPA) in CIN prophylaxis is discussed. While the clinical significance of the effect on nausea of the rolapitant–granisetron–dexamethasone combination after cisplatin is not conclusive, rolapitant addition showed no improvement in nausea prophylaxis after AC or moderately emetogenic chemotherapy (MEC). NEPA was superior to palonosetron in the control of nausea after HEC (AC/cisplatin). Moreover, the efficacy of NEPA in nausea control was maintained over multiple cycles of HEC/MEC. Recently, NK₁RAs have been challenged by olanzapine, with olanzapine showing superior efficacy in nausea prevention after HEC. Fixed antiemetic combinations (such as NEPA) or new antiemetics with a long half-life that may be given once per chemotherapy cycle (rolapitant or NEPA) may improve patient compliance with antiemetic treatment.

National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Antiemesis. Version 2.2016. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 12 August 2016

Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179–185CrossRefPubMed

Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478CrossRefPubMed

Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503CrossRefPubMed

Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Hüsler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715CrossRefPubMed

Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefPubMed

Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefPubMed

Dibble SL, Isreal J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:E40–E47CrossRefPubMed

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRefPubMed

10.

Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381–386CrossRefPubMed

11.

Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMed

12.

Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477CrossRefPubMed

13.

Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121CrossRefPubMed

14.

Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494CrossRefPubMed

15.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119

16.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMed

17.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830CrossRefPubMed

18.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMed

19.

dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Noqueira Lima JP (2012) Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104:1280–1292CrossRefPubMed

20.

Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H (2013) The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:2575–2581CrossRefPubMed

21.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, on behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefPubMed

22.

US Food and Drug Administration (2014) FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418375.htm. Accessed 12 August 2016

23.

European Medicines Agency (2015) Akynzeo http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/003728/smops/Positive/human_smop_000801.jsp&mid = WC0b01ac058001d127. Accessed 12 August 2016

24.

Varubi (rolapitant) [prescribing information] (2015) Waltham, MA: TESARO, Inc. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf. Accessed 12 August 2016

25.

Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34:148–159

26.

Muth ER, Stern RM, Thayer JF, Koch KL (1996) Assessment of the multiple dimensions of nausea: the nausea profile (NP). J Psychosom Res 40:511–520CrossRefPubMed

27.

Napadow V, Sheehan JD, Kim J, Lacount LT, Park K, Kaptchuk TJ, Rosen BR, Kuo B (2013) The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex 23:806–813CrossRefPubMed

28.

Hornby PJ (2001) Central neurocircuitry associated with emesis. Am J Med 111(Suppl 8A):106S–112SCrossRefPubMed

29.

Carpenter DO (1990) Neural mechanisms of emesis. Can J Physiol Pharmacol 68:230–236CrossRefPubMed

30.

Xu LH, Koch KL, Summy-Long J, Stern RM, Seaton JF, Harrison TS, Demers LM, Bingaman S (1993) Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol 265:E578–E584

31.

Sanger GJ, Andrews PL (2006) Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 129:3–16CrossRefPubMed

32.

Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249–262CrossRefPubMed

33.

Morrow GR (1992) Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters. Br J Cancer 66:S38–S41

34.

O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres. CMAJ 149:296–302PubMedPubMedCentral

35.

Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195CrossRefPubMed

36.

Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760CrossRefPubMed

37.

Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMed

38.

Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772CrossRefPubMedPubMedCentral

39.

Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 10:149–157

40.

Majem M, Moreno MA, Calvo N, Feliu A, Perez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983–1990CrossRefPubMed

41.

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915

42.

Rojas C, Slusher BS (2015) Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron). Cancer Treat Rev 41:904–913CrossRefPubMed

43.

Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089CrossRefPubMed

44.

Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16:1071–1078CrossRefPubMed

45.

Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000–1006CrossRefPubMed

46.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol 29:1495–1501CrossRefPubMed

47.

Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178CrossRefPubMed

48.

Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32:101–106CrossRefPubMed

49.

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F, Italian Group for Antiemetic Research (2015) Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 26:1248–1253CrossRefPubMed

50.

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRefPubMedPubMedCentral

51.

Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339CrossRefPubMedPubMedCentral

52.

Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346CrossRefPubMedPubMedCentral

53.

Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834–840CrossRefPubMed

54.

Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M (2015) A phase III trial of aprepitant in colorectal cancer patients receiving oxaliplatin-based chemotherapy (SENRI Trial). Ann Oncol 26(Suppl 4):iv108. Abstract O-001

55.

Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL, Kuebler JP (2012) Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30:3389–3395CrossRefPubMedPubMedCentral

56.

Brafford MV, Glode A (2014) Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol 5:24–29PubMedPubMedCentral

57.

Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRefPubMed

58.

Navari RM, Nagy CK (2015) Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. J Clin Oncol 33(Suppl): abstract 9502

59.

Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186CrossRefPubMed

60.

Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer (2010) A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 39:756–767

61.

Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37CrossRefPubMed

62.

Bošnjak S, Schwartzberg LS, Rizzi G, Borroni ME (2014) Evaluation of nausea control with NEPA, a novel oral combination antiemetic. J Clin Oncol 32(Suppl): abstract 169

63.

Bošnjak S, Stamatovic L, Jordan K, Rizzi G (2015) Prevention of chemotherapy-induced nausea and vomiting (CINV) with NEPA, the first oral combination antiemetic, in patients with gynecological cancers receiving platinum-based chemotherapy. European Society of Gynaecological Oncology Congress; 24–27 October 2015; Nice, France. Abstract ESGO-0356

64.

Carreras EM (2015) Efficacy of the antiemetic combination agent, NEPA, in patients with lung cancer receiving platinum chemotherapy. 16th World Conference on Lung Cancer. MASCC-IASLC Joint Session: Palliative and Supportive Care; 6–9 September; Denver, Colorado. Oral presentation 29.03

65.

Rugo HS, Aapro M, Rizzi G (2015) Nausea control and quality-of-life benefit with NEPA, the first combination agent, in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) chemotherapy. San Antonio Breast Cancer Symposium; 8–12 December 2015; San Antonio, Texas. Abstract P1-10-06

66.

Langford P, Chrisp P (2010) Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid 5:77–90CrossRefPubMedPubMedCentral

67.

Lorusso V, Karthaus M, Aapro M (2015) Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. Future Oncol 11:565–577CrossRefPubMed

68.

Gralla RJ (1983) Metoclopramide. A review of antiemetic trials. Drugs 25(Suppl 1):63–73CrossRefPubMed

69.

European Medicines Agency (2013) Metoclopramide-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/referrals/Metoclopramide-containing_medicines/human_referral_000349.jsp&mid = WC0b01ac05805c516f. Accessed 12 August 2016

70.

Séjourné A, Noal S, Boone M, Bihan C, Sassier M, Andrejak M, Chauffert B (2014) Two cases of fatal encephalopathy related to ifosfamide: an adverse role of aprepitant? Case Rep Oncol 7:669–672CrossRefPubMedPubMedCentral

71.

Schwartzberg L, Oprean C, Cardona-Huerta S, Rizzi G, Rossi G, Palmas M, Karthaus M, Aapro M (2013) No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed-dose combination of netupitant and palonosetron. 55th American Society of Hematology Annual Meeting and Exposition; 7–10 December 2013; New Orleans, Louisiana. Abstract 2949

72.

Aapro M, Jordan K, Palmas M, Clerici G, Rizzi G, Giorgino R (2016) No signals of increased toxicity after concomitant administration of NEPA with etoposide or docetaxel: pooled safety data analysis from 4 pivotal studies. MASCC/ISOO Annual Meeting on Supportive Care in Cancer; 23–25 June 2016; Adelaide, Australia. Abstract MASCC-0565

73.

Blower PR (2003) Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 11:93–100PubMed

74.

Gridelli C, Aapro M (2004) Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients. Support Care Cancer 12:487–496CrossRefPubMed

75.

Rojas C, Slusher BS (2012) Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684:1–7CrossRefPubMed

76.

Andrews PL (2014) Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting? Ann Oncol 25:1258–1259CrossRefPubMed

77.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142CrossRefPubMedPubMedCentral

78.

Bosnjak SM, Dimitrijevic J, Djordjevic F (2016) Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care 10(2):180–188CrossRefPubMed

79.

Dranitsaris G, Molasiotis A, Clemons M, Roeland E, Schwartzberg L, Warr D, Jordan K, Dielenseger P, Aapro M (2016) Development of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting (CINV). MASCC/ISOO Annual Meeting on Supportive Care in Cancer; 23–25 June 2016; Adelaide, Australia. Abstract MASCC-0602

80.

Di Mattei VE, Carnelli L, Carrara L, Bernardi M, Rancoita PM, Bergamini A, Ritella C, Rabaiotti E, Mangili G, Sarno L, Candiani M (2016) Chemotherapy-induced nausea and vomiting in gynecological cancer patients: “treatment-related” and “patient-related” risk factors. MASCC/ISOO Annual Meeting on Supportive Care in Cancer; 23–25 June 2016; Adelaide, Australia. Abstract MASCC-0419

Medicine Matters Oncology

Abstract